# Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

> **NCT00478062** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Hodgkin's antigens-GM-CSF-expressing cell vaccine
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00478062
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2018-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478062, "Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00478062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*